Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Missing a crucial clinical update in a 200-page filing can cost far more than time. Vertex Pharmaceuticals’ biotech disclosures run deep—pipeline R&D spend, Trikafta royalty streams, gene-editing milestones, and collaboration payments are scattered across multiple forms. If you have ever searched “Vertex Pharmaceuticals SEC filings explained simply” or wondered how to track “Vertex Pharmaceuticals insider trading Form 4 transactions” before an FDA decision, you know the challenge.
Stock Titan solves it. Our AI-powered summaries break down every Vertex Pharmaceuticals annual report 10-K simplified, flagging revenue by therapy, risk factors tied to cystic-fibrosis competition, and progress on sickle-cell gene edits. Need the latest “Vertex Pharmaceuticals quarterly earnings report 10-Q filing” or an “8-K material events explained” alert after a pivotal trial read-out? We deliver real-time posts as soon as they hit EDGAR. You’ll also receive instant dashboards of “Vertex Pharmaceuticals Form 4 insider transactions real-time,” highlighting executive buys and sells so you can monitor “Vertex Pharmaceuticals executive stock transactions Form 4” without sifting through raw PDFs.
Use cases professionals rely on include:
- Rapid “Vertex Pharmaceuticals earnings report filing analysis” to compare CF revenue quarter-over-quarter.
- Monitoring board decisions in the “Vertex Pharmaceuticals proxy statement executive compensation” for incentive alignment.
- Staying ahead of partnership announcements with “understanding Vertex Pharmaceuticals SEC documents with AI.”
Whether you’re screening catalyst-driven trades or validating long-term models, our platform pairs comprehensive coverage with approachable insight—so every disclosure, from 10-K to Form 4, works for you.
Vertex Pharmaceuticals (VRTX) Form 144 notice: An individual filer intends to sell 266 shares of Vertex common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of $102,859.54 and approximately 256,390,651 shares outstanding. The securities were acquired on May 1, 2024 via restricted stock vesting from the issuer and were paid as compensation on the same date. The approximate sale date is listed as August 27, 2025. The filer reports no other sales in the past three months and affirms no undisclosed material adverse information.
Vertex Pharmaceuticals (VRTX) returned to solid profitability in Q2-25 after last year’s Alpine IPR&D hit. Product revenue rose 11.3% YoY to $2.94 bn, led by flagship CF combo TRIKAFTA/KAFTRIO ($2.55 bn, +4%) and the first full-quarter contribution from new CF triple ALYFTREK ($157 m). Gene-editing therapy CASGEVY and pain candidate JOURNAVX added $30 m and $12 m, respectively. Other revenue of $21 m reflects regional out-licences of povetacicept.
Cost discipline and the absence of 2024’s $4.4 bn Alpine charge lifted operating income to $1.15 bn (38.8% margin) versus a $3.5 bn loss a year ago. Net income reached $1.03 bn, or $3.99 diluted EPS (vs. LPS $13.92). Six-month revenue grew 7% to $5.73 bn and net income totalled $1.68 bn.
Balance sheet remains robust: cash & equivalents $4.97 bn and total liquidity (cash + marketable securities) $12.0 bn against no drawn debt. YTD operating cash flow was $1.89 bn. Shareholder returns accelerated: $818 m stock buybacks YTD under the $3 bn 2023 plan; a new $4 bn authorisation brings remaining capacity to $4.6 bn.
Strategic/other items:
- $379 m impairment on VX-264 (T1D) recorded in Q1.
- Up-front payments of $10 m (Zai Lab) and $20.6 m (Ono) for povetacicept rights booked as other revenue.
- Gross hedge loss of $192 m hit OCI; $222 m forward liabilities on balance sheet.
- Potential royalty dispute on ALYFTREK with third-party assignee of CFF rights disclosed.
Overall, Vertex shows continued CF franchise strength, early traction from pipeline launches, strong cash generation and active capital returns, partially offset by rising R&D spend and product concentration risk.
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
